Evaluating prior cancer exclusion policy to increase lung cancer trial accrual

评估先前的癌症排除政策以增加肺癌试验的应计数量

基本信息

  • 批准号:
    9108931
  • 负责人:
  • 金额:
    $ 8.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-10 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Despite intensive efforts to increase participation in cancer clinical trials, fewer than two percent of US adults are enrolled in clinical trials. Over 4% of National Cancer Institute-sponsored cooperative group trials fail to complete accrual. Clinical trial eligibility criteria present one of the most significant barriers to study accrual and one ofthe few accrual factors directly controlled by investigators and sponsors. Over time, these criteria have become more numerous and restrictive. Across cancer types, a history of prior cancer is a widespread exclusion criterion in clinical trials. This common practice reflects concerns that a prior cancer diagnosis could interfere with study conduct or outcomes, but there are no data clearly supporting these assumptions. Because this practice hinders accrual, limits generalizability of findings, and discriminates against cancer survivors, we need to understand its basis and implications. In a preliminary analysis, we found that approximately 80% of industry- and government-sponsored lung cancer trials exclude patients with prior cancer. For some trials, we projected that over 18% of lung cancer patients would be excluded for this reason alone, corresponding to more than 200 excluded patients for some large phase 3 trials. The goal of the proposed study is to determine the prevalence and impact of prior cancer among older patients with lung cancer using a large, representative, population-based US dataset. Given the large and growing number of cancer survivors, this research will have important and immediate impact on lung cancer clinical trial design and conduct. For example, if we document equivalent or better survival for those with prior cancer, investigators and sponsors could change or modify this exclusion criterion. In turn, this will increase study accrual and completion rates, resulting in getting better treatments to more patients sooner.
 描述(由申请人提供):尽管为增加癌症临床试验的参与做出了大量努力,但只有不到2%的美国成年人参加了临床试验。超过4%的国家癌症研究所赞助的合作小组试验未能完成累积。临床试验合格性标准是研究累积的最重要障碍之一,也是研究者和申办者直接控制的少数累积因素之一。随着时间的推移,这些标准变得越来越多,越来越严格。在所有癌症类型中,既往癌症史是临床试验中广泛使用的排除标准。这种常见的做法反映了对既往癌症诊断可能干扰研究实施或结果的担忧,但没有数据明确支持这些假设。由于这种做法阻碍了收益,限制了研究结果的普遍性,并歧视癌症幸存者,我们需要了解其基础和含义。在初步分析中,我们发现大约80%的行业和政府赞助的肺癌试验排除了既往癌症患者。对于一些试验,我们预计超过18%的肺癌患者将仅因这一原因而被排除,相当于一些大型III期试验中有200多名患者被排除。这项研究的目的是使用一个大型的、代表性的、基于人群的美国数据集来确定老年肺癌患者中既往癌症的患病率和影响。鉴于癌症幸存者的数量庞大且不断增长,这项研究将对肺癌临床试验的设计和实施产生重要而直接的影响。例如,如果我们记录了先前患有癌症的患者的等同或更好的生存率,研究者和申办者可以改变或修改此排除标准。反过来,这将增加学习应计费用 和完成率,从而更快地为更多患者提供更好的治疗。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers.
  • DOI:
    10.1002/sim.7691
  • 发表时间:
    2018-07-20
  • 期刊:
  • 影响因子:
    2
  • 作者:
    Ge Z;Heitjan DF;Gerber DE;Xuan L;Pruitt SL
  • 通讯作者:
    Pruitt SL
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options.
  • DOI:
    10.1001/jamaoncol.2016.2238
  • 发表时间:
    2016-11-01
  • 期刊:
  • 影响因子:
    28.4
  • 作者:
    Khan SA;Pruitt SL;Xuan L;Gerber DE
  • 通讯作者:
    Gerber DE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Eric Gerber其他文献

David Eric Gerber的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Eric Gerber', 18)}}的其他基金

Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
  • 批准号:
    10630125
  • 财政年份:
    2020
  • 资助金额:
    $ 8.1万
  • 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
  • 批准号:
    10418693
  • 财政年份:
    2020
  • 资助金额:
    $ 8.1万
  • 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
  • 批准号:
    9921601
  • 财政年份:
    2020
  • 资助金额:
    $ 8.1万
  • 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
  • 批准号:
    10376977
  • 财政年份:
    2020
  • 资助金额:
    $ 8.1万
  • 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
  • 批准号:
    10189523
  • 财政年份:
    2020
  • 资助金额:
    $ 8.1万
  • 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
  • 批准号:
    10359155
  • 财政年份:
    2019
  • 资助金额:
    $ 8.1万
  • 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
  • 批准号:
    10062108
  • 财政年份:
    2019
  • 资助金额:
    $ 8.1万
  • 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
  • 批准号:
    10581694
  • 财政年份:
    2019
  • 资助金额:
    $ 8.1万
  • 项目类别:
UT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4
UT 西南 NCI 国家临床试验网络 (NCTN) LAPS - 补充资金 YR4
  • 批准号:
    10733732
  • 财政年份:
    2019
  • 资助金额:
    $ 8.1万
  • 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
UT 西南 NCI 国家临床试验网络主要学术网站 - U10
  • 批准号:
    9248972
  • 财政年份:
    2014
  • 资助金额:
    $ 8.1万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 8.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了